BR112016026552A2 - derivados de carboxamida, seus usos, composição farmacêutica, e combinação - Google Patents

derivados de carboxamida, seus usos, composição farmacêutica, e combinação

Info

Publication number
BR112016026552A2
BR112016026552A2 BR112016026552A BR112016026552A BR112016026552A2 BR 112016026552 A2 BR112016026552 A2 BR 112016026552A2 BR 112016026552 A BR112016026552 A BR 112016026552A BR 112016026552 A BR112016026552 A BR 112016026552A BR 112016026552 A2 BR112016026552 A2 BR 112016026552A2
Authority
BR
Brazil
Prior art keywords
combination
pharmaceutical composition
carboxamide derivatives
carboxamide
derivatives
Prior art date
Application number
BR112016026552A
Other languages
English (en)
Other versions
BR112016026552A8 (pt
BR112016026552B1 (pt
Inventor
Anne-Marie D'souza
Mahbub Ahmed
Robert Alexander Pulz
Lisa Ann Rooney
Nichola Smith
Thomas Josef Troxler
Kamlesh Jagdis Bala
Andrew Brearley
James Dale
David Porter
David Andrew Sandham
Duncan Shaw
Jessica Louise Taylor
Roger John Taylor
Joe Wrigglesworth
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50735903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016026552(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112016026552A2 publication Critical patent/BR112016026552A2/pt
Publication of BR112016026552A8 publication Critical patent/BR112016026552A8/pt
Publication of BR112016026552B1 publication Critical patent/BR112016026552B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR112016026552-1A 2014-05-14 2015-05-14 Derivados de carboxamida, seus usos, composição farmacêutica, e combinação BR112016026552B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14168303.7 2014-05-14
EP14168303 2014-05-14
PCT/US2015/030817 WO2015175796A1 (en) 2014-05-14 2015-05-14 Carboxamide derivatives

Publications (3)

Publication Number Publication Date
BR112016026552A2 true BR112016026552A2 (pt) 2017-08-15
BR112016026552A8 BR112016026552A8 (pt) 2021-07-06
BR112016026552B1 BR112016026552B1 (pt) 2023-02-14

Family

ID=50735903

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016026552-1A BR112016026552B1 (pt) 2014-05-14 2015-05-14 Derivados de carboxamida, seus usos, composição farmacêutica, e combinação

Country Status (38)

Country Link
US (6) US9403810B2 (pt)
EP (1) EP3143018B1 (pt)
JP (1) JP6523338B2 (pt)
KR (2) KR102534033B1 (pt)
CN (1) CN106661012B (pt)
AP (1) AP2016009550A0 (pt)
AR (1) AR100440A1 (pt)
AU (1) AU2015259083B2 (pt)
BR (1) BR112016026552B1 (pt)
CA (1) CA2948543C (pt)
CL (1) CL2016002839A1 (pt)
CR (1) CR20160527A (pt)
CU (1) CU24434B1 (pt)
CY (1) CY1124251T1 (pt)
DK (1) DK3143018T3 (pt)
EA (1) EA030938B1 (pt)
ES (1) ES2874882T3 (pt)
HR (1) HRP20210783T1 (pt)
HU (1) HUE054590T2 (pt)
IL (1) IL248785B (pt)
JO (1) JO3610B1 (pt)
LT (1) LT3143018T (pt)
MA (1) MA39983B1 (pt)
MX (1) MX2016014939A (pt)
MY (1) MY186598A (pt)
PE (1) PE20171443A1 (pt)
PH (1) PH12016502246B1 (pt)
PL (1) PL3143018T3 (pt)
PT (1) PT3143018T (pt)
RS (1) RS61874B1 (pt)
SG (1) SG11201609217UA (pt)
SI (1) SI3143018T1 (pt)
SV (1) SV2016005313A (pt)
TN (1) TN2016000489A1 (pt)
TW (2) TWI714528B (pt)
UY (1) UY36124A (pt)
WO (1) WO2015175796A1 (pt)
ZA (1) ZA201607658B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI714528B (zh) 2014-05-14 2021-01-01 瑞士商諾華公司 甲醯胺衍生物
US9403833B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
MX2020004400A (es) * 2017-11-01 2020-08-06 Bristol Myers Squibb Co Compuestos espirociclicos como moduladores del receptor farnesoide x.
CN108689976B (zh) * 2018-07-23 2021-12-28 陕西师范大学 5-磺基水杨酸协同二氯二茂钛催化合成4-碘代四氢吡喃衍生物的方法
KR20230093251A (ko) 2020-09-10 2023-06-27 프리시릭스 엔.브이. Fap에 대한 항체 단편
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2655009A1 (de) * 1976-12-04 1978-06-15 Hoechst Ag Isoxazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
US7354722B1 (en) 1999-06-11 2008-04-08 Signal Pharmaceuticals Modulators of Smurf and BMP/TGFβ signaling pathways
CA2376675A1 (en) * 1999-06-11 2000-12-21 The Research Foundation Of State University Of New York Antagonists of bmp and tgf.beta. signalling pathways
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
GB0312368D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel ureido- and amido-pyrazolone derivatives
WO2005030128A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors
US7291743B2 (en) 2005-03-29 2007-11-06 Geneblue Corporation Isoxazole derivatives and methods of treating nitric oxide mediated diseases
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
EP2185530B1 (en) 2007-08-02 2011-09-14 N.V. Organon 5-phenyl-isoxazole-3-carboxamide derivatives as trpv1 modulators
RU2455288C2 (ru) 2007-08-22 2012-07-10 Айрм Ллк Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
JP2011507910A (ja) * 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
WO2011151361A1 (en) 2010-06-03 2011-12-08 Glaxo Group Limited Novel compounds
WO2012110986A1 (en) 2011-02-18 2012-08-23 Actelion Pharmaceuticals Ltd Novel pyrazole and imidazole derivatives useful as orexin antagonists
WO2015173659A2 (en) * 2014-05-14 2015-11-19 Novartis Ag Carboxamide derivatives
EP3143021B1 (en) 2014-05-14 2019-06-12 Pfizer Inc Pyrazolopyridines and pyrazolopyrimidines
US9403833B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
TWI714528B (zh) 2014-05-14 2021-01-01 瑞士商諾華公司 甲醯胺衍生物

Also Published As

Publication number Publication date
US10195181B2 (en) 2019-02-05
TW201946921A (zh) 2019-12-16
AU2015259083B2 (en) 2017-09-14
PH12016502246A1 (en) 2017-01-09
CN106661012A (zh) 2017-05-10
CA2948543C (en) 2022-08-16
US20200268718A1 (en) 2020-08-27
HUE054590T2 (hu) 2021-09-28
AR100440A1 (es) 2016-10-05
MA39983B1 (fr) 2021-05-31
CL2016002839A1 (es) 2017-01-27
TWI714528B (zh) 2021-01-01
EA201692300A1 (ru) 2017-04-28
US20170014388A1 (en) 2017-01-19
SV2016005313A (es) 2018-06-12
PL3143018T3 (pl) 2021-08-30
PH12016502246B1 (en) 2017-01-09
ES2874882T3 (es) 2021-11-05
CU20160166A7 (es) 2017-03-03
US20150329529A1 (en) 2015-11-19
KR20170003666A (ko) 2017-01-09
RS61874B1 (sr) 2021-06-30
AP2016009550A0 (en) 2016-11-30
US11672782B2 (en) 2023-06-13
JP6523338B2 (ja) 2019-05-29
UY36124A (es) 2016-01-08
CN106661012B (zh) 2019-12-20
US9403810B2 (en) 2016-08-02
EP3143018A1 (en) 2017-03-22
PT3143018T (pt) 2021-06-01
DK3143018T3 (da) 2021-05-31
EA030938B1 (ru) 2018-10-31
WO2015175796A1 (en) 2015-11-19
NZ725918A (en) 2023-09-29
CY1124251T1 (el) 2022-07-22
ZA201607658B (en) 2017-09-27
MA39983A (fr) 2017-03-22
SI3143018T1 (sl) 2021-08-31
PE20171443A1 (es) 2017-09-29
SG11201609217UA (en) 2016-12-29
JO3610B1 (ar) 2020-08-27
US20210052554A1 (en) 2021-02-25
JP2017515853A (ja) 2017-06-15
LT3143018T (lt) 2021-06-10
CR20160527A (es) 2017-04-28
BR112016026552A8 (pt) 2021-07-06
IL248785A0 (en) 2017-01-31
EP3143018B1 (en) 2021-03-10
CU24434B1 (es) 2019-09-04
MY186598A (en) 2021-07-29
US20190381011A1 (en) 2019-12-19
US20230301970A1 (en) 2023-09-28
KR20230074827A (ko) 2023-05-31
TN2016000489A1 (en) 2018-04-04
IL248785B (en) 2020-04-30
HRP20210783T1 (hr) 2021-06-25
MX2016014939A (es) 2017-02-28
BR112016026552B1 (pt) 2023-02-14
KR102534033B1 (ko) 2023-05-19
TW201623296A (zh) 2016-07-01
CA2948543A1 (en) 2015-11-19
AU2015259083A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
HK1232224A1 (zh) 取代脲衍生物及其在藥物中的應用
HK1243999A1 (zh) 新型3-吲哚取代的衍生物、藥物組合物及使用方法
BR112016016158A2 (pt) Derivados de heterociclila bicíclicos como inibidores de irak4, sua composição farmacêutica e seus usos
CL2016002569A1 (es) Anticuerpos, composiciones farmacéuticas y usos de los mismos
BR112016023422A2 (pt) Dispersão seca por spray, composição farmacêutica e seus usos, kit e comprimido
BR112017009204A2 (pt) Derivados de feniltriazol hidroxialquil- substituído e usos dos mesmos
BR112016000909A2 (pt) derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas
DK3297605T3 (da) Topiske, farmaceutiske sammesætninger
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
BR112016016289A2 (pt) heteroaris e usos dos mesmos
BR112016024298A2 (pt) compostos de quinoxalina e seus usos.
BR112016025659A2 (pt) compostos, seus usos, e composições farmacêuticas para induzir condrogênese
DK3233111T3 (da) Farmaceutisk sammensætning, der omfatter plasminogen, og anvendelser deraf
BR112016026552A2 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
HK1256674A1 (zh) 氘修飾的brigatinib衍生物、含有該化合物的藥物組合物及其用途
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
BR112016027383A2 (pt) Derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação
IL263969A (en) Benzodioxane derivatives and their pharmaceutical use
BR112016027379A2 (pt) formulações tópicas e seus usos
ZA201701066B (en) Pyridine derivatives and anti-mycobacterial use thereof
IL261643B (en) Piperidine derivatives, their preparation and use
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
DK3236934T3 (da) Farmaceutisk sammensætning, fremstilling og anvendelser deraf
DK3157506T3 (da) Smagsmaskeret oral, farmaceutisk sammensætning

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/05/2015, OBSERVADAS AS CONDICOES LEGAIS